Published in Blood Weekly, January 27th, 2000
The studies were designed to assess the safety and efficacy of GA-EPO as a treatment for anemia of renal failure in dialysis and pre-dialysis patients and are intended to support filing for market approval in both the United States and United Kingdom. The data from the trials are being collected, and, if the results are positive, the filings of a Biologics License Application (BLA) to the US Food and Drug Administration and a Marketing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.